DAMORA THERAPEUTICS, INC. Debt Securities, Available-for-sale, Noncurrent
DAMORA THERAPEUTICS, INC. (DMRA) had Debt Securities, Available-for-sale, Noncurrent of $25.49 million as of 2021-09-30, per its 10-Q filed 2021-11-04.
Discontinued › Assets › Assets, Noncurrent › Long-Term Investments
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent · last filed 2021-11-04
- 2021-09-30: Debt Securities, Available-for-sale, Noncurrent $25.49M.
- 2021-06-30: Debt Securities, Available-for-sale, Noncurrent $35.86M.
- 2021-03-31: Debt Securities, Available-for-sale, Noncurrent $38.58M.
| Period end | Debt Securities, Available-for-sale, Noncurrent |
|---|---|
| 2021-09-30 | $25.49M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $35.86M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $38.58M 10-Q · filed 2021-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |